ArticleBMC psychiatry2025
Patients reported neuropsychiatric adverse events and associated factors among PLHIV patients receiving DTG-based regimen antiretroviral therapy real-life clinical practice in Ethiopia: multi center crossetional study.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Perceptions of dolutegravir-based regimen use among people living with HIV in Limpopo province: A qualitative study.Curationis · 2026Article
- Review
- Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDolutegravir-based antiretroviral therapy has established itself as a key component for treating individuals with HIV. In reality, clinical settings in resource-poor areas like Ethiopia often face difficulties when using dolutegravir-based treatment due to neuropsychiatric side effects, which can not only reduce the therapy's effectiveness but also lead to non-adherence, switching, diminished therapeutic outcomes and discontinuation. This research aimed to determine the prevalence and factors related to neuropsychiatric side effects among people living with HIV who recently began receiving Dolutegravir-based Antiretroviral Therapy in real-life clinical settings in Ethiopia.
methodA multicenter cross-sectional study was conducted from December 1, 2023, to August 30, 2023, peoples with HIV who were initiating a Dolutegravir-based regimen for the first time. Data collection was conducted using a structured questionnaire designed to gather sociodemographic, clinical characteristics, and neuropsychiatric adverse effects from patient interviews and medical records. Bivariate and multivariate analyses were employed to identify variables significantly associated with neuropsychiatric adverse events, with P-value of ≤ 0.05.
resultsA total of 620 participants were included in the analysis, revealing a 28.3% prevalence of neuropsychiatric adverse events. The most commonly reported events were depression, insomnia, and aggressive mood. Being female [AOR = 1.72], age between 47 and 54 years [AOR = 3.8] and 55-75 years [AOR = 1.27], unemployment status [AOR = 1.35], lack of physical activity [AOR = 3.6], and minimal of physical activity [AOR = 2.4], duration since DTG-based regimen initiation, 6-12 months[AOR = 3.35], and 13-24 months [AOR = 2.67], WHO clinical stage II [AOR = 3.65], III and IV [AOR = 4.21], Detectable viral load level at the start therapy [AOR = 1.24 (1.97.6-2.05)] were significantly associated with neuropsychiatric adverse events.
conclusionBeing female, aged 47-75 years, unemployed, engaged in minimal or no physical activity, having a treatment duration of 6-24 months, advanced disease stage (WHO stage II-IV) and had a detectable viral load at the start of therapy. Monitoring these groups for neuropsychiatric adverse events is essential to facilitate timely interventions and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.